Danaher Corporation $DHR Stake Lifted by Ritholtz Wealth Management

Ritholtz Wealth Management increased its holdings in Danaher Corporation (NYSE:DHR – Free Report) by 29.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,634 shares of the conglomerate’s stock after acquiring an additional 2,860 shares during the quarter. Ritholtz Wealth Management’s holdings in Danaher were worth $2,799,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DHR. Gunderson Capital Management LLC bought a new position in Danaher during the 3rd quarter valued at $765,000. EP Wealth Advisors LLC acquired a new position in Danaher during the 2nd quarter worth $3,807,000. Frank Rimerman Advisors LLC grew its holdings in Danaher by 181.9% during the 3rd quarter. Frank Rimerman Advisors LLC now owns 40,855 shares of the conglomerate’s stock worth $9,051,000 after acquiring an additional 26,363 shares in the last quarter. Birch Hill Investment Advisors LLC increased its position in shares of Danaher by 9.6% in the 3rd quarter. Birch Hill Investment Advisors LLC now owns 40,549 shares of the conglomerate’s stock worth $8,984,000 after purchasing an additional 3,553 shares during the last quarter. Finally, Forbes J M & Co. LLP increased its position in shares of Danaher by 141.6% in the 3rd quarter. Forbes J M & Co. LLP now owns 4,276 shares of the conglomerate’s stock worth $947,000 after purchasing an additional 2,506 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Danaher stock opened at $233.16 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.29. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The company has a fifty day moving average price of $222.56 and a two-hundred day moving average price of $201.52. The company has a market cap of $164.04 billion, a PE ratio of 38.16, a P/E/G ratio of 2.93 and a beta of 0.76.

Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.17%. The company had revenue of $6.55 billion for the quarter, compared to analysts’ expectations of $6.56 billion. During the same period in the prior year, the company earned $1.89 earnings per share. The firm’s revenue was up 8.3% compared to the same quarter last year. Research analysts expect that Danaher Corporation will post 8.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Wednesday, September 30th. Danaher’s dividend payout ratio is currently 26.19%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent analyst reports. Deutsche Bank restated a “buy” rating and issued a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. Wells Fargo & Company decreased their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 22nd. JPMorgan Chase & Co. lifted their price target on Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, October 22nd. Royal Bank Of Canada boosted their price objective on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Finally, Morgan Stanley upped their price objective on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Eighteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $242.91.

Check Out Our Latest Stock Analysis on Danaher

Insider Transactions at Danaher

In related news, CAO Christopher Bouda sold 7,598 shares of the business’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $234.56, for a total transaction of $1,782,186.88. Following the completion of the sale, the chief accounting officer owned 9,107 shares of the company’s stock, valued at $2,136,137.92. This represents a 45.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregory Milosevich sold 2,100 shares of the stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $230.62, for a total transaction of $484,302.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $5,158,277.54. This trade represents a 8.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 10.80% of the stock is owned by corporate insiders.

About Danaher

(Free Report)

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.